Business Context and Reporting Period
This Form 6-K filing by Nano-X Imaging Ltd. covers the month of August 2026. The company, a foreign private issuer based in Israel, is reporting on a registered direct offering and providing an update regarding its preliminary financial data for the quarter ended June 30, 2026.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The document focuses on a capital raise transaction and a pending accounting assessment rather than finalized financial results.
Material Changes and Transactions
- Registered Direct Offering: On August 5, 2026, the company entered into a purchase agreement to sell 8,000,000 ordinary shares (or pre-funded warrants) and warrants to purchase up to 8,000,000 ordinary shares to a single institutional investor.
- Offering Terms: The combined purchase price is $1.00 per share and warrant (or $0.9999 for pre-funded warrants). The warrants have an exercise price of $1.15, are exercisable after six months, and expire in five years.
- Closing Date: The transaction is expected to close on August 7, 2026, subject to customary conditions.
Outlook, Risks, and Management Commentary
Impairment Assessment: Management disclosed that it has initiated a comprehensive impairment assessment across all assets, including long-lived assets and goodwill, in preparation of financial statements for the three months ended June 30, 2026. An external independent appraiser has been retained to assist in this evaluation.
Financial Uncertainty: The assessment is ongoing and incomplete as of the filing date. Consequently, final reported financial results for the period may differ, potentially materially, from preliminary estimates.
Risks: The primary risk highlighted is the potential for material adjustments to financial results due to the pending impairment charges. Additionally, the offering is subject to customary closing conditions.
Investor Verification Checklist
- Verify the final closing of the registered direct offering on or around August 7, 2026.
- Monitor the completion of the impairment assessment and the resulting impact on the Q2 2026 financial statements.
- Review the final press release (Exhibit 99.1) for any additional terms or conditions not detailed in the summary.
- Confirm the final reported goodwill and long-lived asset values once the impairment assessment is concluded.